Phibro Animal Health (PAHC) Expected to Announce Earnings on Wednesday

Phibro Animal Health (NASDAQ:PAHC) is expected to be issuing its Q2 2026 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of $0.69 per share and revenue of $355.6360 million for the quarter. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, February 5, 2026 at 9:00 AM ET.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.The firm had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. On average, analysts expect Phibro Animal Health to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Phibro Animal Health Stock Performance

Shares of PAHC stock opened at $39.52 on Wednesday. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32. Phibro Animal Health has a 52 week low of $16.16 and a 52 week high of $46.42. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of 23.81, a PEG ratio of 1.12 and a beta of 0.79. The stock has a fifty day moving average of $39.97 and a 200 day moving average of $37.69.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 17th. Investors of record on Wednesday, November 26th were paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend was Wednesday, November 26th. Phibro Animal Health’s dividend payout ratio is presently 28.92%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on PAHC shares. JPMorgan Chase & Co. increased their target price on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Finally, Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $31.40.

Insider Activity

In related news, CEO Jack Bendheim sold 38,303 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $45.29, for a total value of $1,734,742.87. Following the completion of the sale, the chief executive officer directly owned 20,577 shares of the company’s stock, valued at approximately $931,932.33. This represents a 65.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 154,635 shares of company stock worth $6,702,107. Insiders own 50.13% of the company’s stock.

Hedge Funds Weigh In On Phibro Animal Health

A number of hedge funds have recently modified their holdings of PAHC. Danske Bank A S bought a new stake in shares of Phibro Animal Health during the 3rd quarter valued at $955,000. Advisory Services Network LLC purchased a new stake in Phibro Animal Health in the 3rd quarter worth $96,000. Dark Forest Capital Management LP bought a new stake in Phibro Animal Health during the third quarter valued at about $2,751,000. Virtus Advisers LLC lifted its position in shares of Phibro Animal Health by 922.9% in the third quarter. Virtus Advisers LLC now owns 48,576 shares of the company’s stock valued at $1,965,000 after acquiring an additional 43,827 shares in the last quarter. Finally, Polymer Capital Management US LLC purchased a new position in shares of Phibro Animal Health in the third quarter valued at about $286,000. 99.34% of the stock is currently owned by institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.